跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
找到 931 条关于
“VLTR-559”
全部
931
临床试验
514
药物
301
机构
5
资讯
111
5个月前
Valitor's VLTR-559 Shows Extended Six-Month Durability in Wet AMD Preclinical Studies
去年
Valitor's VLTR-559 Shows Favorable Safety Profile in Preclinical Studies for Twice-Yearly Wet AMD Treatment
去年
Accent Therapeutics' ATX-559, a First-in-Class DHX9 Inhibitor, Receives FDA IND Clearance for Solid Tumor Trial
去年
Accent Therapeutics to Showcase Novel Cancer Therapeutics ATX-559 and ATX-295 at AACR 2025
去年
Accent Therapeutics Doses First Patient in Phase 1/2 Trial of DHX9 Inhibitor ATX-559
11个月前
Accent Therapeutics Unveils Promising Preclinical Data for Novel Cancer Therapies ATX-295 and ATX-559 at Major Oncology Conference
去年
Accent Therapeutics Initiates Phase I/II Trial of Novel KIF18A Inhibitor for Advanced Solid Tumors
7年前
FGFR1 Overexpression Identified as a Key Resistance Mechanism to CDK4/6 Inhibitors in ER+ Breast Cancer
去年
GAO Report Highlights Incomplete Reporting in DOD and VA Biomedical Research
11个月前
Boehringer Ingelheim Acquires First-in-Class Oncology Asset from Accent Therapeutics Targeting High ISG Expression Tumors
第 1 页,共 12 页
上一页
下一页